Lodz

• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• A study to test a medicine (fitusiran) injected under the skin for preventing bleeding episodes in male adolescent or adult participants wit … Ended recruitment
  2022-500221-33-01 5 2023-07-28 Hemophilia
• Phase II, Multicenter Study to Assess Safety and Efficacy of Combination of Sargramostim with D-VCd Therapy (Daratumumab, Cyclophosphamide, … Ended recruitment
  2024-518658-18-00 4 2023-07-26 Light chain amyloidosis (AL amyloidosis) is an incurable plasma cell n
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115. Ended recruitment
  2023-505643-39-00 1 2023-07-17 Spinal muscular atrophy
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended recruitment
  2024-515027-11-00 4 2023-06-29 Crohn’s disease
• Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended recruitment
  2022-502145-10-00 5 2023-06-06 Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Ended recruitment
  2022-500700-22-00 5 2023-05-25 Active Systemic Lupus Erythematosus (SLE)
• A research study looking at how safe somapacitan is and how well it works in children who need help to grow – REAL 9 Ended recruitment
  2022-501055-87-01 5 2023-05-18 Noonan syndrome
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A study to test product setrusumab in subjects with brittle bone syndrome. Ended recruitment
  2024-510919-29-00 10 2023-05-08 Osteogenesis imperfecta (OI)
• A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unex … Ended recruitment
  2024-513462-19-00 5 2023-03-30 Refractory Chronic Cough, Including Unexplained Chronic Cough
• A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une … Ended recruitment
  2024-513460-26-00 5 2023-03-29 Refractory Chronic Cough, Including Unexplained Chronic Cough
• A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung c … Ended recruitment
  2024-511169-12-00 5 2023-03-28 Non-Small Cell Lung Cancer
• A Phase 2b Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC Ended recruitment
  2022-500953-17-00 4 2023-03-23 Moderately to severely active ulcerative colitis
• A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy Ended recruitment
  2024-512785-33-00 10 2023-03-01 Active Idiopathic Inflammatory Myopathy (IIM)
• REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended recruitment
  2023-506924-94-00 5 2023-02-28 Cardiovascular disease
• A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended recruitment
  2022-501744-15-00 5 2023-01-23 Obesity, Overweight
• Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mut … Ended recruitment
  2024-511548-19-00 1 2022-12-13 Pancreatic Ductal Adenocarcinoma
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit … Ended recruitment
  2023-504743-13-00 4 2022-11-30 Moderately to Severely Active Ulcerative Colitis
• RemiRit - Personalized immunosuppressive therapy with rituximab in the treatment of ANCA associated vasculitis - a randomized, multicenter c … Ended recruitment
  2024-517881-40-00 4 2022-11-27 Antineutrophil cytoplasmic antibody (ANCA)- associated vasculitis (AAV
• OM 85 in Paediatric Recurrent Respiratory Tract Infections with Wheezing Lower Respiratory Illness Ended recruitment
  2024-511581-37-00 6 2022-11-25 Respiratory Tract Infections with Wheezing Lower Respiratory Illness

Showing 529–552 of 898 trials